
- Pharmaceutical Technology, January 2022 Issue
- Volume 46
- Issue 1
Next-Generation Cas9 Proteins
Thermo Fisher's Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency.
Thermo Fisher Scientific’s Invitrogen TrueCut Hifi Cas9 Protein is designed for research applications that require highly precise genome editing, such as the engineering of chimeric antigen receptor (CAR)-T cells and the creation of cellular models for disease discovery.
The Invitrogen TrueCut HiFi Cas9 Protein significantly reduces off-target events while retaining maximum on-target editing efficiency. It does this by minimizing edits in unintended locations, which are disruptive in translational research, drug screening, and drug modeling. It has demonstrated near complete elimination of off-target effects compared to wild-type Cas9 in several cell types, including T cells and induced pluripotent stem cells (iPSCs), as well as shown improved off-target profiles relative to similar proteins.
Articles in this issue
almost 4 years ago
Industrious Pharmaceuticalsalmost 4 years ago
The Long Path to Normalalmost 4 years ago
Changes Afoot: 2022 Outlook for Pharma and its Peoplealmost 4 years ago
Addressing the Training Gap for Single-Use Technologiesalmost 4 years ago
The Need for Speed: How Operation Warp Speed Shifted the Pharma Industryalmost 4 years ago
Taste and Appearance: Selecting the Right Excipientsalmost 4 years ago
Tackling the Big Issue of Solubilityalmost 4 years ago
Biologics Testing Highlights Need for Analytical Skillsalmost 4 years ago
Outsourcing’s Race Toward Noveltyalmost 4 years ago
Regulating Digital TherapeuticsNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.




